期刊
ANALYST
卷 134, 期 8, 页码 1601-1607出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/b904321g
关键词
-
资金
- Hungarian Scientific Fund [OTKA NF 69262]
- National Institutes of Health [EB002189, GM07178]
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002189] Funding Source: NIH RePORTER
An enzyme-linked immunosorbent assay (ELISA) for prostate specific antigen (PSA) detection in human serum was developed based on the potentiometric detection of 6,8-difluoro-4-methylumbelliferone (DiFMU). The assays were carried out in anti-human PSA capture antibody modified microtiter plates (150 mu L volume). After incubation in the PSA-containing serum samples, beta-galactosidase-labeled PSA tracer antibody was added. The beta-galactosidase label catalyzed the hydrolysis of 6,8-difluoro-4-methylumbelliferyl-beta-D-galactopyranoside (DiFMUG) and the resulting DiFMU(-) anion was detected by potentiometric microelectrodes with anion-exchanger membrane. The selectivity of the anion-exchanger electrode is governed by the lipophilicity of the anions in the sample. Since DiFMU(-) is much more lipophilic (log P = 1.83) than any of the inorganic anions normally present in the working buffers and occurs in its anionic form at the physiological pH (pK(a) = 4.19), it was chosen as the species to be detected. The potentiometric ELISA-based method detects PSA in serum with a linear concentration range of 0.1-50 ng/mL. These results confirm the applicability of potentiometric detection in diagnostic PSA assays. Owing to simple methodology and low cost, potentiometric immunoassays seem to offer a feasible alternative to the development of in vitro diagnostic platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据